MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

Core Insights - MiNK Therapeutics presented new data on its allo-iNKT cell therapy, agenT-797, demonstrating its potential to enhance immune activation in patients with refractory gastroesophageal cancer when combined with checkpoint inhibitors and chemotherapy [1][2][3] Combination Therapy Efficacy - The combination of agenT-797 with botensilimab and balstilimab showed significant immune reactivation, leading to improved clinical activity in tumors that typically do not respond to treatment [2][3] - Early induction of agenT-797 resulted in a notable increase in interferon-gamma (IFNγ) levels and enhanced tumor infiltration by T cells and antigen-presenting cells, indicating robust systemic immune engagement [3] Treatment Sequencing Importance - The most effective immune response was observed when agenT-797 was administered concurrently with checkpoint inhibitors and prior to standard chemotherapy, highlighting the significance of treatment sequencing [4] Strategic Advantages - MiNK's scalable manufacturing process allows for the generation of billions of donor-derived iNKT cells in a single run, facilitating rapid global distribution and reducing logistical challenges [6] - The company’s differentiated pipeline supports expansion into additional hard-to-treat cancers, presenting significant opportunities for growth and partnerships [6] Product Overview - AgenT-797 is designed to leverage both innate and adaptive immunity, functioning as a "master regulator" to enhance immune responses against difficult tumors [9][10] - Botensilimab and balstilimab are designed to improve anti-tumor immune responses, particularly in "cold" tumors that are less responsive to conventional therapies [11][12]